ANALYSIS: Trump Imposes Tariffs on Medicines and Metals — Protectionism Becomes a Weapon of Mass Economic Destruction

When Protectionism Kills

There is a fundamental difference between taxing an imported flat-screen TV and taxing insulin. We can do without the flat-screen TV. We cannot do without insulin. Diabetic patients, who already pay astronomical sums for their treatments, do not have the luxury of waiting for the American industry to restructure. Their bodies do not negotiate.

Tariffs on medications will automatically drive up prices for the end consumer. That’s arithmetic, not ideology. Pharmaceutical companies that import active ingredients will pass on the extra cost. Insurers will pass it on. And at the end of the chain is Maria, 67, in Topeka, Kansas, who is already choosing between her medications and groceries.

The U.S. pharmaceutical industry has voluntarily outsourced

No one forced Pfizer, Johnson & Johnson, or Merck to manufacture their drugs in India. They did so because the profit margins were better, regulations were less restrictive, and labor was cheaper. That was pure capitalism—the very kind the Republican Party celebrates in all its speeches. Blaming the consequences of decisions that the system has encouraged for thirty years is not industrial policy—it’s punitive theater.

And yet, not a single Big Pharma executive will take the podium at the White House to explain why those factories left. This silence is deafening. This silence is complicit.

Without lithium, there are no batteries. Without batteries, there is no sovereignty

The metals targeted by the executive order are not just any commodities. Lithium, cobalt, rare earth elements, and titanium—these are the building blocks of the energy transition, the defense industry, and artificial intelligence. Every drone, every guided missile, every electric vehicle, and every AI server contains these materials.

The United States mines only a tiny fraction of its rare earth needs. China controls more than 60% of global production and more than 85% of refining. Taxing these imports without having developed alternative sources is tantamount to shooting oneself in the strategic foot—and reloading the gun for the next foot.

The Paradox of National Defense

The irony is almost poetically cruel. Trump justifies these tariffs in the name of national security. But the first to suffer from the rising cost of these metals will be U.S. defense contractors—Lockheed Martin, Raytheon, Northrop Grumman—who rely heavily on imports of Russian titanium and Chinese rare earths to manufacture the fighter jets and missile systems ordered by the Pentagon.

Protecting national security by driving up the cost of the very weapons that national security requires. If a Hollywood screenwriter proposed this plot, it would be rejected for lack of plausibility.

Europe Is Already Planning Its Retaliation

Brussels didn’t wait 24 hours to respond. The European Commission announced that it was preparing targeted countermeasures—a diplomatic euphemism for: we’re going to slap tariffs on Kentucky bourbon, Harley-Davidsons from Wisconsin, and soybeans from Iowa. The same products, the same swing states, the same logic of surgical electoral pressure that worked in 2018.

Transatlantic trade is worth more than 1,100 billion dollars a year. This isn’t just a trade relationship—it’s an ecosystem. And every unilateral tariff is a blow with an axe to the trunk of that ecosystem. The tree doesn’t fall immediately. But the roots, they die in silence.

Canada and Mexico: Permanent Collateral Damage

The USMCA—the North American free trade agreement that Trump himself renegotiated in 2020—has now been stripped of its substance by the ever-increasing number of tariff exemptions. Ottawa and Mexico are watching their trading partner tear up the contract it signed itself. Trust—that invisible currency that lubricates international trade—evaporates with every new executive order.

And yet, Canada supplies the United States with a significant portion of its aluminum, potash, and uranium. Imposing tariffs on your leading supplier of strategic raw materials while asking it to remain a loyal NATO ally—it takes a certain degree of cognitive audacity to view this as a coherent strategy.

The Founding Lie

Since 2018, Trump has repeatedly claimed that it is the exporting countries that pay the tariffs. This claim has been refuted by every serious economic study published on the subject. The National Bureau of Economic Research, the Federal Reserve Bank of New York, and Princeton University—all reach the same conclusion: tariffs are paid by U.S. importers, who pass them on to U.S. consumers.

This is not an opinion. It is not a theory. It is accounting. The container of medicines arriving at the Port of Los Angeles pays the tariff to U.S. Customs. The U.S. importer writes the check. And the importer adds this cost to the final price. Every cent of the tariff is a cent of hidden tax on the American consumer.

The Most Regressive Tax of All

Tariffs disproportionately hit the poorest households the hardest. A billionaire doesn’t feel the difference when the price of his medication goes up by 15%. A family living on minimum wage does. Tariffs are, by design, the most regressive form of taxation that exists—and they are being imposed by a president who claims to defend the working class.

The contradiction is not subtle. It is grotesque. It is well-documented. And it is ignored by an electoral base whose tribal loyalty now outweighs any analysis of its own economic interests.

Beijing Isn’t Panicking—Beijing Is Diversifying

While Washington issues a flurry of executive orders, Beijing is building. China has accelerated its investments in pharmaceutical value chains in Southeast Asia. It is consolidating its metal supply agreements with Africa and Latin America. It is developing alternatives to the dollar in bilateral transactions.

Every U.S. tariff pushes third countries toward trade agreements that exclude the United States. The RCEP, the world’s largest free-trade agreement, does not include Washington. The New Silk Road does not wait for the White House’s approval. The world does not stop trading just because the United States decides to shut itself off—the world trades without them.

The Strategic Mistake of the Century

By simultaneously targeting China, Europe, Canada, Mexico, India, and South Korea, Trump is achieving what no U.S. adversary has ever managed: he is uniting the rest of the world against U.S. trade policy. Countries that had no reason to coordinate their trade policies suddenly find themselves with a common enemy.

Sun Tzu put it this way 2,500 years ago: never fight on all fronts at once. This age-old wisdom clearly did not survive the journey from the Library of Congress to the Oval Office.

The markets are playing Russian roulette with the real economy

The financial markets reacted with their usual erratic behavior. An initial drop, followed by a rebound on the hope that tariffs will be negotiated down. This cycle has been repeating itself for eight years. Volatility has become structural. High-frequency trading algorithms love it. Pension funds managing the retirement savings of millions of Americans, not so much.

The VIX—the “fear index”—surges with every announcement and then drops again when a Trump advisor murmurs the word “negotiation” in a White House hallway. This isn’t economics. It’s a game of bluffing on a global scale, and the chips on the table are the jobs, savings, and health of real people.

The Hidden Cost of Uncertainty

Every company that postpones an investment because of tariff uncertainty is a job left uncreated. Every factory whose project is on hold while waiting to see whether tariffs will be maintained, increased, or eliminated in six months is a community that stagnates. Uncertainty doesn’t show up in any official statistics, but it eats away at the economic fabric like a slow-acting acid.

American CEOs surveyed by the Business Roundtable now rank regulatory and tariff uncertainty as their top concern—ahead of inflation, interest rates, and Chinese competition. When business leaders fear their own government more than their competitors, something has fundamentally broken.

The Pharmacist of the Developing World

India produces more than 60% of the world’s vaccines and an overwhelming proportion of the generic drugs consumed globally. Taxing Indian pharmaceutical exports to the United States not only punishes India—it undermines the entire global healthcare system.

Indian generic drugs provide hundreds of millions of people in developing countries with access to treatments for HIV, tuberculosis, and malaria. If India redirects its production capacity to compensate for losses in the U.S. market, it is the poorest countries that will foot the bill. U.S. protectionism has collateral victims who have never set foot in the United States and will never vote in a U.S. election.

New Delhi is recalibrating its alliances

Narendra Modi’s India is no longer the docile India of the 1990s. It is a power with 1.4 billion people that negotiates simultaneously with Washington, Moscow, and Beijing. Every U.S. tariff strengthens the arguments of those in New Delhi who advocate for accelerated rapprochement with China and strategic distancing from the United States.

Trump wants India to serve as a counterweight to China in the Indo-Pacific. But at the same time, he is imposing tariffs on Indian exports. Asking someone to be your ally while emptying their pockets—that’s a strategy that has a name in diplomacy: utter inconsistency.

The Ghost of Smoot-Hawley

In 1930, Senators Reed Smoot and Willis Hawley pushed through the most protectionist tariff law in American history. More than 20,000 imported products were hit with massive tariffs. The result: a 66% contraction in global trade over four years, a catastrophic worsening of the Great Depression, and a spiral of retaliatory measures that helped poison international relations for the following decade.

Every economic historian knows this precedent. Every international trade textbook cites it. And yet, we are watching the same play unfold all over again, with the same lines, the same promises, and the same certainties. The costumes have changed. The folly remains the same.

What Smoot-Hawley Really Teaches Us

The lesson from 1930 is not that tariffs are always bad. It is that unilateral, massive, and non-negotiated tariffs trigger spirals of retaliation that no one can control. Every country reacts. Every retaliatory measure invites a counter-retaliation. And collective rationality collapses under the weight of economic nationalism.

We’re not quite back to 1930 yet. But the direction is clear. The speed is alarming. And the driver refuses to look in the rearview mirror.

Ohio workers won’t see the promised factory

In the deindustrialized valleys of Ohio, Pennsylvania, and Michigan, voters who supported Trump are still waiting for the promised manufacturing jobs. Steel mills protected by the 2018 tariffs have hired a few hundred people. Downstream industries that use steel—automotive, construction, machinery—have lost tens of thousands of jobs due to rising costs.

The net result is negative. This isn’t a projection—it’s a finding verified by the Federal Reserve Bank of Chicago, the Peterson Institute for International Economics, and every research institute that has bothered to do the math. Protecting one upstream job by destroying three downstream jobs isn’t industrial policy—it’s electoral arithmetic disguised as patriotism.

Unanswered Rage

And yet, these same voters continue to support this policy. Not because they fail to see its effects—their grocery bill reminds them of them every week—but because their rage against a system that has betrayed them for forty years is stronger than the rational calculation of their immediate self-interest. They want someone to strike a blow. Even if that fist lands right on their own faces.

Understanding this rage without condemning it is the most difficult task in contemporary political analysis. For this rage is legitimate. It is the responses to it that are catastrophic.

When Shortages Become Structural

The Food and Drug Administration is already managing a list of drug shortages that has never been longer. Antibiotics, anesthetics, and cancer treatments are regularly in short supply in U.S. hospitals. Imposing tariffs on imported active pharmaceutical ingredients will automatically exacerbate these shortages.

A surgeon at Mount Sinai Hospital in New York who has to postpone an operation because an anesthetic is unavailable isn’t thinking about tariffs. He’s thinking about the patient on the operating table. And between Washington’s protectionist theory and the surgical reality in New York, there is a chasm that presidential executive orders will not bridge.

Healthcare Staff on the Brink of Collapse

After three years of the pandemic, after waves of burnout, after the mass exodus of healthcare workers, adding drug shortages caused by trade policy is like asking an exhausted marathon runner to run one more sprint. Nurses who are already juggling insufficient supplies will have to juggle even scarcer supplies and even more anxious patients.

No one in the Oval Office seems to have asked this very simple question: Did you speak to a doctor before signing this executive order?

The global reserve currency will not last forever

Every unilateral U.S. decision accelerates the de-dollarization of global trade. This process is slow, gradual, and almost imperceptible over the course of a single presidential term. But it is real. China, Russia, Brazil, India, and Saudi Arabia—all are exploring alternatives to the dollar for their bilateral trade.

The dollar’s exorbitant privilege—its unique ability to finance its deficits by printing the currency the whole world wants to hold—rests on trust. Trust in the stability of U.S. institutions. Trust in the predictability of U.S. policy. Trust that signed agreements will be honored. Every surprise tariff, every impulsive executive order, every threat on Twitter erodes that trust by an invisible millimeter—but the millimeters add up.

The Day the World Stops Financing America

The United States lives beyond its means because the rest of the world lends to it at exceptionally low rates. This global generosity is not charity—it is a calculation of self-interest based on the dollar’s centrality. If that centrality wanes, U.S. borrowing rates rise, the cost of debt skyrockets, and Washington’s fiscal house of cards begins to crumble.

This scenario isn’t going to happen overnight. But every day of erratic tariff policy brings tomorrow closer to today.

The Lobby Groups That Profit from the Chaos

Behind every tariff decree, there are silent winners. American steel producers who benefit from protection. Agricultural lobbies that negotiate exemptions. International trade consultants whose order books explode with every new wave of tariffs. Regulatory chaos isn’t a glitch in the system—for some, it’s a feature.

Always follow the money. Who funded the campaign? Who had the president’s ear before the signing? Who secured a discreet exemption two weeks after the public announcement? These questions aren’t conspiracy theories—they’re matters of accounting.

Spectacle as Strategy

Every tariff announcement generates a 48-hour media cycle. Forty-eight hours during which no one talks about Medicaid budget cuts, no one talks about controversial judicial appointments, and no one talks about the erosion of civil rights. Tariffs are a spectacular smokescreen—loud, visible, emotional—behind which far more profound transformations unfold in calculated silence.

And yet, every time, the media takes the bait. Every time, the cycle repeats itself. The question is no longer whether Trump has mastered media manipulation—it’s when the media will stop willingly participating in the spectacle.

Deaths Hidden in Trade Statistics

When a medication costs 25% more because of customs duties, some patients reduce their doses. Others stop their treatment. Still others never even begin the prescribed treatment. These silent decisions, made in the solitude of a suburban kitchen, don’t make the headlines. They don’t generate presidential tweets. They don’t cause stock market reactions.

But they kill.

A study by the RAND Corporation estimated that every 10% increase in the price of prescription drugs leads to a 2% to 6% drop in treatment adherence among low-income patients. Translate those percentages into preventable heart attacks, uncontrolled diabetes, and cancers diagnosed too late. Tariffs take a toll on lives. It’s just too diffuse to be captured in a photograph.

Ethics Left Out of the Calculation

No White House cost-benefit analysis factors in the lives lost due to rising drug costs. The impact is calculated in dollars, jobs, and the trade balance. Never in years of life lost. Never in avoidable suffering. Never in dignity taken away.

When trade policy is conceived exclusively in terms of financial flows, human beings become externalities. And externalities, by definition, are not counted.

A president who confuses action with progress

Donald Trump signs executive orders. Lots of them. Pens wear out, cameras roll, supporters cheer. But signing isn’t building. Announcing isn’t accomplishing. Taxing isn’t producing.

The reindustrialization of the United States is a legitimate goal. It is even a vital goal. But it requires a twenty-year strategy, not twenty-second tweets. It requires investment in vocational training, infrastructure, and research. It requires patience—that virtue which American politics has forgotten amid four-year election cycles and three-second algorithms.

What Could Have Been Done

Imagine for a moment an alternative policy. Massive tax credits for companies that bring pharmaceutical production back home. Public-private partnerships to develop strategic metal mines on American soil with strict environmental standards. Bilateral agreements with allies to diversify supply chains away from China without punishing everyone. The carrot before the stick. Building before destruction.

This policy exists in analysts’ reports that no one reads. It is feasible. It is effective. It just doesn’t make headlines. And in the America of 2026, what doesn’t make headlines doesn’t exist.

Ultimately, what April 3, 2026, reveals is not just a trade policy—it is the state of a democracy that confuses strength with brutality, patriotism with isolation, and sovereignty with loneliness. Medicines will cost more. Metals will cost more. And somewhere in a small American town, someone will have to choose between getting medical care and putting food on the table. That person has no lobbyist. That person has no platform. That person just has a body that needs care and a wallet that says no.

Signed, Jacques PJ Provost